| NĚMEC, Pavel, Zuzana ZEMANOVÁ, Kyra MICHALOVÁ, Jana TAJTLOVÁ, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Romana ZAORALOVÁ, Ivan ŠPIČKA, Evžen GREGORA, Dana KRÁLOVÁ, Renata KUPSKÁ, Marta KREJČÍ, Luděk POUR, Lenka ZAHRADOVÁ, Viera SANDECKÁ, Zdeněk ADAM, Petr KUGLÍK and Roman HÁJEK. Gain/amplification of 1q21 is the most powerful genetic prognostic factor for patients treated by autologous stem cell transplantation. In Haematologica/The Hematology Journal. 2008. ISSN 0390-6078. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{814132,
author = {Němec, Pavel and Zemanová, Zuzana and Michalová, Kyra and Tajtlová, Jana and Grešliková, Henrieta and Filková, Hana and Zaoralová, Romana and Špička, Ivan and Gregora, Evžen and Králová, Dana and Kupská, Renata and Krejčí, Marta and Pour, Luděk and Zahradová, Lenka and Sandecká, Viera and Adam, Zdeněk and Kuglík, Petr and Hájek, Roman},
booktitle = {Haematologica/The Hematology Journal},
keywords = {multiple myeloma; gain1q21; autologous stem cell transplantation},
language = {eng},
title = {Gain/amplification of 1q21 is the most powerful genetic prognostic factor for patients treated by autologous stem cell transplantation},
year = {2008}
}
TY - CONF
ID - 814132
AU - Němec, Pavel - Zemanová, Zuzana - Michalová, Kyra - Tajtlová, Jana - Grešliková, Henrieta - Filková, Hana - Zaoralová, Romana - Špička, Ivan - Gregora, Evžen - Králová, Dana - Kupská, Renata - Krejčí, Marta - Pour, Luděk - Zahradová, Lenka - Sandecká, Viera - Adam, Zdeněk - Kuglík, Petr - Hájek, Roman
PY - 2008
TI - Gain/amplification of 1q21 is the most powerful genetic prognostic factor for patients treated by autologous stem cell transplantation
KW - multiple myeloma
KW - gain1q21
KW - autologous stem cell transplantation
N2 - Our data suggest that gain1q21 is associated with reduced PFS and OS intervals in patients treated with autologous transplantation. Similarly a trend towards shorter survival for del17p13 positive patients was observed. Moreover, negative prognostic impact of gain1q21 can be boosted by presence of any other studied chromosomal aberration, which implicates much poorer outcome for patients carrying those aberrations together (data not shown). The treatment response of MM patients is not significantly influenced by any of the analyzed chromosomal abnormality. Presence of gain1q21 is significantly associated with presence of del(17p). Considering observation of unfavourable prognostic impact of gain1q21 either with or without correlation of any other studied aberrations, gain1q21 seems to be the most powerful independent prognostic factor for newly diagnosed MM patients treated by autologous stem cell transplantation.
ER -
NĚMEC, Pavel, Zuzana ZEMANOVÁ, Kyra MICHALOVÁ, Jana TAJTLOVÁ, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Romana ZAORALOVÁ, Ivan ŠPIČKA, Evžen GREGORA, Dana KRÁLOVÁ, Renata KUPSKÁ, Marta KREJČÍ, Luděk POUR, Lenka ZAHRADOVÁ, Viera SANDECKÁ, Zdeněk ADAM, Petr KUGLÍK and Roman HÁJEK. Gain/amplification of 1q21 is the most powerful genetic prognostic factor for patients treated by autologous stem cell transplantation. In \textit{Haematologica/The Hematology Journal}. 2008. ISSN~0390-6078.
|
